Genotyping results, laboratory diagnosis, and epidemiology of the mumps virus circulating in the Czech Republic in 2012

Czech version

Authors: R. Limberková; P. Lexová
Authors‘ workplace: Státní zdravotní ústav, Centrum epidemiologie a mikrobiologie, Praha
Published in: Epidemiol. Mikrobiol. Imunol. 63, 2014, č. 1, s. 36-42
Category: Review articles, original papers, case report

Overview

Goal:
To extend the present routine serological diagnosis of mumps with the methods of direct detection of the pathogen and subsequent genotyping of the isolated viruses in an attempt to obtain more detailed data on recent mumps viruses circulating in the Czech Republic. Sub-goals were to point out the particularities of the laboratory examination in the population with a high vaccine coverage and to evaluate the current epidemiological situation.

Material and methods:
Altogether 47 buccal swabs from patients with suspected mumps were included in the study. Clinical specimens collected at the onset of clinical symptoms were obtained from five administrative regions of the Czech Republic from February 2012 to December 2012. Vero cell cultures were used for virus isolation and isolates were identified using real-time quantitative polymerase chain reaction (RT-qPCR). Genotyping was performed by the WHO Regional Reference Laboratory for Measles, Mumps, and Rubella (RRL MMR), Robert Koch Institute, Berlin. The EPIDAT system was used as a source of epidemiological data.

Results:
From 47 buccal swabs, 20 mumps viruses were isolated on Vero cells and in seven other specimens, the presence of viral RNA without positive isolation was only detected by RT-qPCR. Nineteen isolates were referred for genotyping. The phylogenetic analysis of the SH gene classified them into genotype G, as four variants. In both 2011 and 2012, most cases occurred in vaccinated patients (80%), with 15–19-year-olds being the most affected age group. The leading complication was orchitis, followed by meningitis. More complications were reported in non-vaccinated individuals.

Conclusions:
The increased incidence of mumps cases in the Czech Republic in 2012 was due primarily to genotype G, the leading cause of mumps in most European countries since 2005. The presence of genotype G was first reported in the Czech Republic in 2006. In the context of the unfavourable epidemiological trend, molecular epidemiological studies including genotyping of recent mumps virus strains appear to be necessary. A detailed monitoring could be helpful in elucidating the pattern of virus circulation and in designing strategies to control emerging outbreaks. The vaccination efficacy in relation to the causative genotype and possible role of waning immunity in mumps outbreaks are the issues that need to be addressed.

Keywords:
mumps virus – laboratory diagnosis – genotypes – epidemiology

Sources

1. Lennette EH. Diagnostic procedures for viral, rickettsial, and chlamydia infections. Seventh edition, Washington: American public health association; 1995; 455–465 s. ISBN: 0-87553-220-9.

2. Liebert UG. Viruses and pregnancy. Intervirology, 1998(41):145–148.

3. Petráš M, Lesná IK. Manuál očkování 2010. 3.vyd., Praha 2010; 202 – 217 s. ISBN: 978-80-254-5419-0

4. WHO Mumps virus nomenclature update: 2012. Weekly Epidemiological Record, 2012;87: 217–224.

5. Whelan J, van Binnendijk R, Greenland K, Fanoy E, et al. Ongoing mumps outbreak in student population with high vaccination coverage, Netherlands 2010. Euro Surveill, 2010;15(17):pii=19554. Dostupné na www:

http://www.eurosurveillance.org/ViewArticle.aspx?Articled = 19554.

6. Walker J, Huc S, Sinka K, Tissington A, et al. Ongoing outbreak of mumps infection in Oban, Scotland, November 2010 to January 2011. Euro Surveill. 2011;16(8):pii=19803. Dostupné na www: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19803

7. Otto W, Mankertz A, Santibanez S, Saygili H, et al. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Euro Surveill, 2010;15(50):pii=19748. Dostupné na www:

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19748

8. Kuzmanovska G, Polozhani A, Mikik V, Stavridis K, et al. Mumps outbreak in the former Yugoslav Republic of Macedonia, January 2008–June 2009: epidemiology and control measures. Euro Surveill, 2010;15(23): pii=19586. Dostupné na www:

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19586.

9. Mrázová M, Smelhausová M, Sestáková Z, Svandová E, Benes C. The 2001 serological survey in the Czech Republic-mumps. Cent Eur J Public Health, 2003;11: Suppl.:S50-3.

10. Decision No 2008/426/EC amending Decision No 2002/253/EC laying down case definitions for reporting communicable diseases to Community network under Decision No 2119/98/EC of European Parliament and of the Council.

11. Vyhláška č. 473/2008 Sb., o systému epidemiologické bdělosti pro vybrané infekce, ve znění pozdějších předpisů.

12. Laboratory testing for mumps infection. Dostupné na www: http://www.cdc.gov/mumps/lab/index.html.

13. Davidkin I, Jokinen S, Paananen A et al. Etiology of mumps-like illness in children and adolescents vaccinated for measles, mumps and rubella. J Infect Dis, 2005;191:719–723.

14. Mühlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol, 2004;4:215–219.

15. Cui A, Brown DWG, Xu W, Jin L (2013). Genetic variation in the HN and SH genes of mumps viruses: A comparison of strains from mumps cases with and without neurological symptoms. PloS ONE 8(4):e61791.doi:10.1371/journal.pone0061791.

16. Montes M, Cilla G, Artieda J, Vicente D, et al. Mumps outbreak in vaccinated children in Gipuzkoa (Basque Country), Spain. Epidemiol Infect, 2002;129:551–556.

17. Nöjd J, Tecle T, Samuelsson A, Örvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine, 2001;19:1727–1731.

18. WHO. Global status of mumps immunization and surveillance. Weekly Epidemiological Record, 2005;80(48):418–424.

19. Galazka AM, Robertson SE, Kraiger A. Mumps and mumps vaccine: global review. Bulletin WHO, 1999;77:3–14.

20. Kubínyiová M, Beneš C, Príkazský V, Roubalová K, Cástková J. Mumps vaccination in the Czech Republic. Euro Surveill, 2008;13(27):pii=18920. Dostupné na www:

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18920.

21. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assesment of primary vaccine failure and waning vaccine-induced imunity. J Infect Dis, 1994;169:77–82.

22. Kaaijk P, Zeijst BA, Boog MC, Hoitink CW: Increased mumps incidence in the Netherlands: Review on the possible role of vaccine strain and genotype. Euro, Surveill, 2008;13(26):pii=18914

Dostupné na www:

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18914.

23. Rubin SA, Qi L, Audet SA, Sullivan B, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis, 2008;198(4):508–515. doi: 10.1086/590115